Global Plan to end TB 2016-2020
Moving from accelerated burden reduction to malaria elimination in Zambia
BMJ,Dodd PJ, et al. Thorax 2017;72:559–575. doi:10.1136/thoraxjnl-2016-209421
Copenhagen, Denmark, 24–25 August 2017
UNAIDS 2017 / Reference
Generating evidence for policy and action on HIV and social protection
Topics in Antiviral Medicine Volume 25 Issue 2 May/June 2017
A compendium of TB REACH case studies, lessons learned and a monitoring and evaluation framework.
Accessed November 2017.
Report: A survey conducted among the 27 high MDR-TB burden countries.
March – July 2015
Stop TB Partnership in collaboration with Medecins Sans Frontieres (MSF).
Accessed November 2017.
National Tuberculosis and Leprosy Conrol Programme
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more
Asia Pac J Oncol Nurs 2017;4:4-5.